Pfizer-BioNTech Win Prix Galien Canada Innovative Product Award for COMIRNATY

eAwaz Medicine

KIRKLAND, QUEBEC and MAINZ, GERMANY – Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that COMIRNATY, the Pfizer-BioNTech COVID-19 Vaccine, has been named the 2023 winner of the Prix Galien Canada Innovative Product Award. COMIRNATY is indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) in individuals 6 months of age and older.

One of the most prestigious awards in the field of Canadian pharmaceutical research and innovation, Prix Galien Canada recognizes the efforts and achievements in this field. The annual award was presented at a gala ceremony in Montreal on November 15, 2023.

The Prix Galien Canada Innovative Product Award is presented every year to the company that has developed a drug product or vaccine launched on the Canadian market and judged by the jury to have made the most significant overall contribution to patient care in Canada in terms of efficacy, safety, benefits, and innovation.

“We are honoured that COMIRNATY has been awarded with the 2023 Prix Galien Canada – Innovative Product Award and even prouder of the impact that Pfizer and BioNTech have had on Canada’s response to the COVID-19 pandemic since the authorization of this product in December 2020,” said Najah Sampson, President, Pfizer Canada. “It was the first COVID-19 vaccine to be authorized in this country, and to date over 66 million doses have been administered in Canada. Pfizer has a long-standing legacy in vaccines that is driven by scientific research and development and is deep-rooted in our commitment to preventing infections.”

The COVID-19 vaccines (COMIRNATY®) by Pfizer and BioNTech are based on BioNTech’s proprietary mRNA technology and were developed by both companies. BioNTech is the Marketing Authorization Holder for COMIRNATY and its adapted vaccines (COMIRNATY Original/Omicron BA.4/BA.5; COMIRNATY Omicron XBB.1.5) in the United States, the European Union, the United Kingdom, Canada and other countries, and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries.